IBIO Archives - Page 5 of 8

Executive Moves

iBio appoints global biotech operations expert, Randy Maddux, as COO

Randy Maddux iBio (NYSE AMERICAN:IBIO) appointed biotech industry veteran, Randy Maddux, as COO, effective Dec. 1. Mr. Maddux has more than 20 years of global biologics drug development and manufacturing, business...

November 3, 2020

Executive Moves

iBio appoints accomplished financial executive, Gary Sender, to board

Gary Sender iBio (NYSE AMERICAN:IBIO) appointed senior financial executive, Gary Sender, as a director and a member of the board’s compensation committee. In addition, Mr. Sender was appointed chair of iBio’s audit...

October 15, 2020

Executive Moves

iBio appoints senior biopharma executive, Dr. Alexandra Kropotova, to board

Alexandra Kropotova iBio (NYSE AMERICAN:IBIO) appointed senior biopharma executive, Dr. Alexandra Kropotova, as a director and a member of the board’s new science and technology committee. Dr. Kropotova has expertise in...

October 15, 2020

Executive Moves

iBio appoints renowned biopharma executive, Dr. Linda Armstrong, to board

iBio (NYSE AMERICAN:IBIO) appointed Dr. Linda Armstrong, a renowned biopharma executive, as a director and a member of the board’s new science and technology committee. “We are pleased to welcome Dr. Armstrong to our...

October 14, 2020

Developments

iBio inks agreement with Safi Biosolutions to develop blood cell therapy products

iBio (NYSE AMERICAN:IBIO) entered into an agreement with Safi Biosolutions to develop growth factors and cytokines using iBio’s FastPharming system. Safi is the cell therapy commercialization partner for a five-year U.S...

October 2, 2020

Developments

iBio featured on ABC affiliate

KXXV, an ABC affiliate in Bryan, Texas, published an article on iBio’s (NYSE AMERICAN:IBIO) two COVID-19 vaccine candidates. The company recently reported that it has selected IBIO-201 as its leading candidate for...

September 11, 2020

Developments

iBio selects IBIO-201 as its leading COVID-19 vaccine candidate

iBio (NYSE AMERICAN:IBIO) selected IBIO-201 as its leading candidate for the prevention of SARS-CoV-2 infection. iBio previously reported that both of its COVID-19 vaccine candidates, IBIO-200 and IBIO-201, in...

September 9, 2020

Developments

iBio and Planet Biotechnology in pact to develop COVID-19 therapeutic

iBio (NYSE AMERICAN:IBIO) entered into an exclusive worldwide license agreement with Planet Biotechnology for the development of Planet’s COVID-19 therapeutic candidate, ACE2-Fc. ACE2-Fc is a recombinant protein...

August 28, 2020

Developments

IBIO-201 demonstrates ability to elicit anti-SARS-CoV-2 immune response in preclinical studies

iBio (NYSE AMERICAN:IBIO) reported initial results from preclinical studies of IBIO-201, one of its two COVID-19 vaccine candidates. IBIO-201 is a subunit vaccine that combines antigens derived from the SARS-CoV-2 spike...

August 10, 2020

Developments

The Hill’s coronavirus report features iBio COVID-19 vaccine candidates and FastPharming System

iBio’s (NYSE AMERICAN:IBIO) two COVID-19 vaccine candidates and FastPharming manufacturing system were featured on The Hill’s coronavirus report on July 30. The company is developing IBIO-200 and IBIO-201, virus-like...

July 30, 2020

Tag - IBIO

iBio appoints global biotech operations expert, Randy Maddux, as COO

iBio appoints accomplished financial executive, Gary Sender, to board

iBio appoints senior biopharma executive, Dr. Alexandra Kropotova, to board

iBio appoints renowned biopharma executive, Dr. Linda Armstrong, to board

iBio inks agreement with Safi Biosolutions to develop blood cell therapy products

iBio featured on ABC affiliate

iBio selects IBIO-201 as its leading COVID-19 vaccine candidate

iBio and Planet Biotechnology in pact to develop COVID-19 therapeutic

IBIO-201 demonstrates ability to elicit anti-SARS-CoV-2 immune response in preclinical studies

The Hill’s coronavirus report features iBio COVID-19 vaccine candidates and FastPharming System

General

More